---
schema_version: "secwatch.filing_event.v1"
accession: "0001654954-23-002266"
form_type: "8-K"
ticker: null
cik: "0000896747"
company_name: "AMERICAN BIO MEDICA CORP"
filed_at: "2023-03-01T23:59:59+00:00"
generated_at: "2026-06-18T19:39:23.323573+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# American Bio Medica completes sale of substantially all assets for $3M; CEO departs

## Summary
- Sale closed Feb 28, 2023; purchase price $3M, with $300K held back for indemnification claims.
- Net proceeds to company $247K after paying $965K loan, $1.031M mortgage, $252K unsecured loan, and $205K taxes.
- CEO Melissa Waterhouse employment terminated March 1; she will consult up to 3 months for $4K/month retainer, payment suspended.
- Waterhouse deferred $92K salary and $29K current salary until ERC refund of $202K or retention fund release.
- Company now seeks new line of business or business combination using publicly traded stock.

## SEC filing metadata
- accession: 0001654954-23-002266
- form_type: 8-K
- cik: 0000896747
- company_name: AMERICAN BIO MEDICA CORP
- filed_at: 2023-03-01T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 2.01, 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/896747/000165495423002266/0001654954-23-002266-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/896747/000165495423002266/abmc_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001654954-23-002266
- JSON: https://secwatch.observer/filing/0001654954-23-002266.json
- Plain text: https://secwatch.observer/filing/0001654954-23-002266.txt

## Key facts
- Executive change
  Melissa A. Waterhouse was terminated as Chief Executive Officer at AMERICAN BIO MEDICA CORP.
  - Action: terminated
  - Role: Chief Executive Officer
  source text: the employment agreement with the Company’s Chief Executive Officer/ Principal Financial Officer, Melissa Waterhouse, was terminated effective March 1, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/896747/000165495423002266/0001654954-23-002266-index.htm
- M&A Transactions
  AMERICAN BIO MEDICA CORP completed a disposition involving Healgen Scientific Limited Liability Company for $3 million (closed 2023-02-28).
  - Action: disposition
  - Counterparty: Healgen Scientific Limited Liability Company
  - Consideration: $3 million
  - Closing: 2023-02-28
  source text: the Company’s assets. In connection with the closing of the Sale, and in accordance with the terms of the Asset Purchase Agreement, the Buyer paid an aggregate purchase price of $3 million (“Purchase Price”). $300,000 of the Purchase Price is being held back in a retention fund to cover potential indemnification claims during the six months following the close. Net
  evidence_url: https://www.sec.gov/Archives/edgar/data/896747/000165495423002266/0001654954-23-002266-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.